Canertinib 2HCl, an irreversible quinazoline-based HER family tyrosine kinase inhibitor, inhibits EGFR and ErbB2 with IC50 of 1.5 nM and 9.0 nM respectively. Phase II.
More Information Supplier Page
Canertinib 2HCl, an irreversible quinazoline-based HER family tyrosine kinase inhibitor, inhibits EGFR and ErbB2 with IC50 of 1.5 nM and 9.0 nM respectively. Phase II.
More Information Supplier Page Canertinib 2HCl, an irreversible quinazoline-based HER family tyrosine kinase inhibitor, inhibits EGFR and ErbB2 with IC50 of 1.5 nM and 9.0 nM respectively. Phase II.
More Information Supplier Page 
Canertinib 2HCl, an irreversible quinazoline-based HER family tyrosine kinase inhibitor, inhibits EGFR and ErbB2 with IC50 of 1.5 nM and 9.0 nM respectively. Phase II.
More Information Supplier Page
Trifluorothymidine is a derivative of thymidine that can inhibit thymidylate synthase and lead to DNA damage and apoptosis. It could be used to treat colorectal cancer.
More Information Supplier Page
BTS is a potent and selective inhibitor of Ca2+-stimulated myosin S1 ATPase with IC50 value of ~5 µM.
More Information Supplier Page
BTS is a potent and selective inhibitor of Ca2+-stimulated myosin S1 ATPase with IC50 value of ~5 µM.
More Information Supplier Page
Ambrisentan is an oral, once-daily endothelin receptor antagonist that is selective for the endothelin type A receptor (IC50s = 0.251, 0.316, 0.398, 251, and 630 nM for rat preparations of heart, bladder, kidney, lung, and cerebral cortex, respectively).
More Information Supplier Page
